Hikma Adds Remsima SC To Celltrion MENA Collaboration
Subcutaneous Version Of Infliximab Joins Three Other Celltrion Biosimilars
Hikma has added Celltrion’s Remsima SC subcutaneous formulation of biosimilar infliximab to a marketing alliance in the MENA region that already includes three other Celltrion biosimilars.
